Stifel Nicolaus initiated its coverage on ImunoGen IMGN with a Hold rating.
Stifel Nicolaus said, "Given the relatively short lifespan of the T-DM1 royalty stream (compared to the branded life span of most biologic therapies, such as Epogen, Rituxan, and Herceptin itself, which can run 15-20 years), we expect ImmunoGen to re-invest the royalties as opposed to driving EPS growth. As a result, we believe there is little upside potential for the shares from current levels, even if T-DM1 sales exceed expectations."
ImmunoGen closed at $13.92 on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in